GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Xuemei Zhang1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, US Food and Drug Administration, Jefferson, Arkansas, USA

Maosheng Huang2 The University of Texas MD Anderson Cancer Center, Houston, Texas, US Food and Drug Administration, Jefferson, Arkansas, USA

Xifeng Wu2 The University of Texas MD Anderson Cancer Center, Houston, Texas, US Food and Drug Administration, Jefferson, Arkansas, USA

Susan Kadlubar1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, US Food and Drug Administration, Jefferson, Arkansas, USACorrespondence[email protected]

Jie Lin2 The University of Texas MD Anderson Cancer Center, Houston, Texas, US Food and Drug Administration, Jefferson, Arkansas, USA

Xinfeng Yu1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, US Food and Drug Administration, Jefferson, Arkansas, USA

Chunyang Fan3 VA hospital, Little Rock, Arkansas, US Food and Drug Administration, Jefferson, Arkansas, USA

Baitang Ning4 National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA

Fred F Kadlubar1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, US Food and Drug Administration, Jefferson, Arkansas, USA

show all

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date